Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 1/5/2018 |
| Start Date: | April 2013 |
| End Date: | July 7, 2016 |
Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study
Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or
to build resistance to stress or diseases in indigenous medical systems in India for
centuries. Modern scientific data for WSE indicate several bioactive molecules (withanolides,
withanosides, indosides, withaferin-A, others) with significant immunomodulatory,
anti-inflammatory and stress reducing properties.
This study will examine whether a standardized extract of Withania Somnifera (WSE; Sensoril®)
will improve total, positive, negative symptoms, and stress in patients with schizophrenia.
The study will examine whether WSE reduces PANSS positive and negative symptoms and stress
scores in subjects, and whether these improvements are mediated by changes in inflammatory
immune indices. An additional aim will determine if patients receiving WSE will have fewer
adjustments to their psychotropic medications that those assigned to placebo. The study will
examine whether WSE will re-balance Th1/Th2 ratios (cytokine measures) and mediate a
reduction of elevated hs-CRP levels. It is hypothesized that those subjects whose Th1/Th2
ratios normalize will likely have a greater magnitude of clinical improvement versus those
subjects whose immune ratios remain unbalanced.
The proposal is a 12-week, double-blind, placebo-controlled RCT of WSE added to antipsychotic
medications in approximately 60 or more patients with schizophrenia with an exacerbation of
symptoms. If efficacy is affirmed, this low cost extract could be studied further, and used
quite readily across low, middle and high income countries.
to build resistance to stress or diseases in indigenous medical systems in India for
centuries. Modern scientific data for WSE indicate several bioactive molecules (withanolides,
withanosides, indosides, withaferin-A, others) with significant immunomodulatory,
anti-inflammatory and stress reducing properties.
This study will examine whether a standardized extract of Withania Somnifera (WSE; Sensoril®)
will improve total, positive, negative symptoms, and stress in patients with schizophrenia.
The study will examine whether WSE reduces PANSS positive and negative symptoms and stress
scores in subjects, and whether these improvements are mediated by changes in inflammatory
immune indices. An additional aim will determine if patients receiving WSE will have fewer
adjustments to their psychotropic medications that those assigned to placebo. The study will
examine whether WSE will re-balance Th1/Th2 ratios (cytokine measures) and mediate a
reduction of elevated hs-CRP levels. It is hypothesized that those subjects whose Th1/Th2
ratios normalize will likely have a greater magnitude of clinical improvement versus those
subjects whose immune ratios remain unbalanced.
The proposal is a 12-week, double-blind, placebo-controlled RCT of WSE added to antipsychotic
medications in approximately 60 or more patients with schizophrenia with an exacerbation of
symptoms. If efficacy is affirmed, this low cost extract could be studied further, and used
quite readily across low, middle and high income countries.
The primary aim is to determine whether a standardized extract of Withania somnifera will
reduce psychopathology scores (PANSS total) and stress scores(PSS total) in persons with
schizophrenia?
The study will also determine whether WSE reduces measures of positive and negative and
general symptoms of schizophrenia (PANSS subscale scores)?
Another primary aim will be to determine if changes in antipsychotic and/or other
psychotropic medications (lithium, anticonvulsants, antidepressants, anxiolytic agents or
hypnotics) (examples: dosage escalation or reductions or switch or stoppage) will favor the
group receiving the standardized Withania somnifera extract versus those receiving placebo.
Even though we expect changes in antipsychotic medications to occur when patients experience
an exacerbation of psychotic symptoms (or other psychiatric symptoms), we hypothesize that
those receiving the standardized Withania somnifera extract will experience fewer medication
adjustments then those assigned to placebo.
A secondary aim is to determine whether WSE will rebalance TH1/TH2 ratios (cytokine measures)
and mediate a reduction of elevated hs-CRP levels? The study will assess whether those
subjects whose TH1/TH2 ratios normalize have a greater magnitude of clinical improvement vs.
those subjects whose immune ratios remain unbalanced. Similarly, the study will assess
whether reduction of hsCRP levels correlate with improvements in PANSS total and subscale
scores or the PSS total scores.
Eighty or more patients with DSM IV TR (or if instituted by the study initiation: DSM V)
schizophrenia or schizoaffective disorder will be screened and 60 or more eligible patients
will be enrolled in a 12 week placebo controlled double blind study. Subjects who have
experienced an exacerbation of positive symptoms (delusions, hallucinations, etc). Subjects
receiving medications that affect the immune-inflammatory system will be excluded and those
receiving antibiotics, antiviral or anti-parasitic medications will be excluded.
Base line laboratory and EKG examination will be carried out to establish eligibility for
study participation. In addition specific laboratory analyses of immune markers namely
interleukin-2, interferon gamma, interleukin-4, interleukin 6 and high sensitivity C-Reactive
Protein will be carried out.
Sixty or more patients will be randomly assigned to receive either WSE or matching placebo
starting with 1 capsule of 250 mg strength twice a day (total daily dose = 500 mg) for the
first week which will be increased to 2 capsules of 250 mg twice daily (total daily dose =
1000 mg) for a total treatment period of 12 weeks. An assessment of psychopathology (PANSS)
and stress will be carried out at each scheduled visit. Assessments of safety including vital
signs and treatment emergent adverse events will also be carried out at each visit.
Immune-inflammatory markers will be re-assessed at the final visit.
reduce psychopathology scores (PANSS total) and stress scores(PSS total) in persons with
schizophrenia?
The study will also determine whether WSE reduces measures of positive and negative and
general symptoms of schizophrenia (PANSS subscale scores)?
Another primary aim will be to determine if changes in antipsychotic and/or other
psychotropic medications (lithium, anticonvulsants, antidepressants, anxiolytic agents or
hypnotics) (examples: dosage escalation or reductions or switch or stoppage) will favor the
group receiving the standardized Withania somnifera extract versus those receiving placebo.
Even though we expect changes in antipsychotic medications to occur when patients experience
an exacerbation of psychotic symptoms (or other psychiatric symptoms), we hypothesize that
those receiving the standardized Withania somnifera extract will experience fewer medication
adjustments then those assigned to placebo.
A secondary aim is to determine whether WSE will rebalance TH1/TH2 ratios (cytokine measures)
and mediate a reduction of elevated hs-CRP levels? The study will assess whether those
subjects whose TH1/TH2 ratios normalize have a greater magnitude of clinical improvement vs.
those subjects whose immune ratios remain unbalanced. Similarly, the study will assess
whether reduction of hsCRP levels correlate with improvements in PANSS total and subscale
scores or the PSS total scores.
Eighty or more patients with DSM IV TR (or if instituted by the study initiation: DSM V)
schizophrenia or schizoaffective disorder will be screened and 60 or more eligible patients
will be enrolled in a 12 week placebo controlled double blind study. Subjects who have
experienced an exacerbation of positive symptoms (delusions, hallucinations, etc). Subjects
receiving medications that affect the immune-inflammatory system will be excluded and those
receiving antibiotics, antiviral or anti-parasitic medications will be excluded.
Base line laboratory and EKG examination will be carried out to establish eligibility for
study participation. In addition specific laboratory analyses of immune markers namely
interleukin-2, interferon gamma, interleukin-4, interleukin 6 and high sensitivity C-Reactive
Protein will be carried out.
Sixty or more patients will be randomly assigned to receive either WSE or matching placebo
starting with 1 capsule of 250 mg strength twice a day (total daily dose = 500 mg) for the
first week which will be increased to 2 capsules of 250 mg twice daily (total daily dose =
1000 mg) for a total treatment period of 12 weeks. An assessment of psychopathology (PANSS)
and stress will be carried out at each scheduled visit. Assessments of safety including vital
signs and treatment emergent adverse events will also be carried out at each visit.
Immune-inflammatory markers will be re-assessed at the final visit.
Inclusion Criteria:
1. Adult males or females (≥ 18 years, to 75 years)
2. DSM IV TR diagnosis of schizophrenia or schizoaffective disorder (If officially
instituted by study initiation: DSM V diagnoses will be used).
3. Ability to provide informed written consent
4. PANSS total score ≥ 60, positive symptom cluster, (delusions, conceptual
disorganization, hallucinatory behavior, excitement, grandiosity,
suspiciousness/persecution, hostility and unusual thought content with at least 2
items scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 =
absent to 7 = extreme
5. Current symptom exacerbation ≥ 2 weeks, but ≤ 1 year
6. Receiving anti-psychotic medications for ≥ 4 weeks
7. For women of child bearing age, a negative pregnancy test at screening.
Exclusion Criteria:
1. Testing positive for illicit substances (marijuana or alcohol use will be assessed on
a case by case basis, caffeine and nicotine are excepted)
2. Receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate,
others) will be reviewed on a case by case basis
3. Seriously unstable medical illnesses
4. Pregnant or breast feeding women
5. Known allergy or history of serious adverse event with WSE
6. Subjects who may require imminent hospitalization (examples: suicidal or aggressive
behavior)
7. Currently receiving antibiotics, anti-viral, or anti-parasitic medications
8. Currently receiving immunosuppressive medications (e.g. corticosteroids, chemotherapy
or transplantation or HIV/AIDs associated drugs).
9. Currently receiving NSAIDs or Aspirin (>81 mg/day) on a daily basis or PRN use >
2x/week (in the last 4 weeks).
We found this trial at
1
site
Pittsburgh, Pennsylvania 15213
Principal Investigator: KN Roy Chengappa, MD
Phone: 412-246-5258
Click here to add this to my saved trials
